Fidaxomicin: In clostridium difficile infection

Drugs

Volumn 71, Issue 18, 2011, Pages 2445-2456

  Duggan, Sean T ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Clostridium infections; Diarrhoea; Fidaxomicin

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL RNA; CYCLOSPORIN; CYTOCHROME P450; DIFICLIR; DIGOXIN; DRUG METABOLITE; FIDAXOMICIN; MACROLIDE; METRONIDAZOLE; MIDAZOLAM; OMEPRAZOLE; OP 1118; RIFAMPICIN; RIFAXIMIN; STAPHYLOCOCCUS ENTEROTOXIN A; STAPHYLOCOCCUS ENTEROTOXIN B; UNCLASSIFIED DRUG; VANCOMYCIN; WARFARIN;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; BACTERIAL STRAIN; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DIARRHEA; DRUG ABSORPTION; EMBASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HOSPITALIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLORA; MEDLINE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SINGLE DRUG DOSE; SPOROGENESIS; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 82955240575     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208220-000000000-00000     Document Type: Review

References (47)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society ofAmerica (IDSA). Infect Control Hosp Epidemiol 2010 May; 31 (5): 431-55
2. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006 Mar; 12 (3): 409-15
3. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007 Sep; 13 (9): 1417-9 (Pubitemid 47510317)
4. Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nat Rev Gastroenterol Hepatol 2011; 8 (6): 330-9
5. Bauer MP, Kuijper EJ, van Dissel JT, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009 Dec; 15 (12): 1067-79
6. Poxton IR. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol 2010 Apr; 5 (4): 539-48
7. Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008 Jul; 52 (7): 2403-6 (Pubitemid 351915669)
8. Dificid (fidaxomicin) tablets: US prescribing information. San Diego (CA): Optimer Pharmaceuticals, 2011
9. Center for Drug Evaluation and Research. Medical review of fidaxomicin (difficid) [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda docs/nda/2011/201699Orig1s000ClinPharmR.pdf [Accessed 2011 Sep 20]
10. Louie T, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of C. difficile infection and reduces toxin re-expression and recurrence of CDI [abstract no. 1418]. 48th Annual Meeting of the Infectious Diseases Society of America; 2010 Oct 20-23; Vancouver (BC)
11. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010 Nov; 156 (Pt 11): 3354-9
12. Theriault RJ, Karwowski JP, JacksonM, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics: I. Taxonomy, fermentation and antibacterial activity. J Antibiot (Tokyo) 1987 May; 40 (5): 567-74 (Pubitemid 17072152)
13. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007 Aug; 51 (8): 2716-9 (Pubitemid 47206204)
14. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008 Nov; 52 (11): 4163-5
15. Finegold SM,Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004 Dec; 48 (12): 4898-902
16. Bouillaut L, Babakhani F, SonensheinAL. Fidaxomicin inhibits Clostridium difficile toxin synthesis and sporulation [abstract no. C1-635]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
17. Sims C, Gomez A, Sears SP, et al. Fidaxomicin inhibits production of toxin A and toxin B in Clostridium difficile [abstract no. C1-634]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
18. Ackermann G, Loffler B, Adler D, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004 Jun; 48 (6): 2280-2 (Pubitemid 38691631)
19. Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991 Jun; 35 (6): 1108-11
20. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004 Nov; 48 (11): 4430-4 (Pubitemid 39434908)
21. Goldstein EJC, Citron DM, Sears P, et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 2011; 55 (11): 5194-9
22. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011 Feb 3; 364 (5): 422-31
23. Johnson S, Crook DW, Cornely OA, et al. Randomized clinical trial (RCT) in Clostridium difficile infection (CDI) confirms superiority of fidaxomicin over vancomycin [abstract no. 711c]. Digestive Disease Week; 2010 May 1-6; New Orleans (LA)
24. Crook D, Weiss K, Cornely OA, et al. Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs vancomycin [abstract no. LB2401]. 20th European Congress of Clinical Microbiology and Infectious Diseases; 2010 Apr 10-13; Vienna
25. Babakhani F, Gomez A, Robert N, et al. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011; 60 (Pt 8): 1213-7
26. Babakhani F, Seddon J, Robert N, et al. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile. Antimicrob Agents Chemother 2010 Jun; 54 (6): 2674-6
27. Biedenbach DJ, Ross JE, Putnam SD, et al. In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother 2010May; 54 (5): 2273-5
28. DuPont HL. The search for effective treatment of Clostridium difficile infection. New Engl J Med 2011; 364 (5): 473-5
29. Babakhani F, Gomez A, Robert N, et al. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother 2011 Sep; 55 (9): 4427-9
30. Seddon J, Babakhani F, Gomez A, et al. RNA polymerase target modification in Clostridium difficile with reduced susceptibility to fidaxomicin [abstract no. C1-631]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
31. Louie T, Cannon K, St Denis M, et al. Quantitative realtime PCR measurement of the impact of fidaxomicin or vancomycin treatment of Clostridium difficile infection on the intestinal microbiome, compared with normal controls [abstract no. P676]. 20th European Congress of Clinical Microbiology and Infectious Diseases; 2010 Apr 10-13; Vienna
32. Louie TJ, Emery J, Krulicki W, et al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of Clostridium difficile infection. Antimicrob Agents Chemother 2009 Feb; 53 (1): 261-3
33. Nerandzic MM, Mullane K, Miller M, et al. Acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection [abstract no. K-1915]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco (CA)
34. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008 Apr; 52 (4): 1391-5 (Pubitemid 351522003)
35. Lewis W, Sears SP. Minimal impact of food on the pharmacokinetics of oral fidaxomicin [abstract no. A2-042]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
36. Lewis W, Sears PS. Effect of cyclosporine on the pharmacokinetics of fidaxomicin [abstract no. A2-045]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
37. Lewis W, Tang M, Sears PS. Minimal effect of fidaxomicin on digoxin pharmacokinetics [abstract no. A2-043]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
38. Lewis W, Sears PS. Coadministration of fidaxomicin does not impact the pharmacokinetics of CYP substrates omeprazole, warfarin, ormidazolam [abstract no. A2-044]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
39. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009 Jan; 53 (1): 223-8
40. Sears P, Louie T, Mullane K, et al. Pharmacokinetics/pharmacodynamics of fidaxomicin in treatment of Clostridium difficile infection [abstract no. A1-1949]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco (CA)
41. Sears PS, Crook DW, Louie TJ, et al. High fecal and low plasma levels of fidaxomicin and metabolite OP-1118 in patients with C. difficile infection: combined results of two phase 3 trials [abstract no. Mo1160]. Gastroenterology 2011 May; 140 (5 Suppl. 1): S571
42. Crook D, Peto T, Miller M, et al. Efficacy and safety of fidaxomicin (FDX) vs vancomycin (VAN) in Clostridium difficile infection (CDI) in 2 randomized controlled trials (RCT) with 1105 patients [abstract no. 1417]. 48th Annual Meeting of the Infectious Diseases Society of America; 2010 Oct 21-24; Vancouver (BC)
43. Golan Y, Louie TJ, Miller M, et al. Risk of recurrence and time to recurrence following treatment of Clostridium difficile infection: patient characteristics and the differential effect of fidaxomicin vs. vancomycin [abstract no. Sa1981]. Gastroenterology 2011; 140 (5 Suppl.): S360-1
44. Cornely OA, Miller M, Louie T, et al. Randomized controlled Trial (RCT) of fidaxomicin (FDX) versus vanco-mycin (VAN) in treatment of recurrent Clostridium difficile infection (CDI) [abstract no. L1-1305]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12-15; Boston (MA)
45. Gerding DN, Sambol SP, Nagaro K, et al. Clostridium difficile strain type as determined by restriction endonuclease analysis in two phase III trials of fidaxomicin vs vancomycin: treatment outcome for the epidemic BI/NAP1/027 strain [abstract no. L1-1306]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sept 12-15; Boston (MA)
46. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for concurrent infections. Clin Infect Dis 2011 Sep; 53: 440-7
47. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of opinion for Dificlir (fidaxomicin) [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Sum mary-of-opinion---Initial-authorisation/human/002087/WC500112845.pdf [Accessed 2011 Nov 3]